Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2000
06/20/2000US6077845 As analgesic for alleviating pain
06/20/2000US6077843 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
06/20/2000US6077841 For treating sexual disorders, male impotency, heart failure, pulmonary hypertension, and angina
06/20/2000US6077839 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
06/20/2000US6077838 Method of treating hangover
06/20/2000US6077837 Administering prodrug to mammal comprising protein kinase inhibitor covalently bonded to transporting adjuvant, the covalent bond being cleaved in presence of supernormal enzyme activity to treat conditions like stroke, epilepsy, asthma
06/20/2000US6077836 Peritoneal dialysis and compositions for use therein
06/20/2000US6077834 Combining non-viral receptor ligand and cationic lipid ; adding polynucleotide to form molecular mixture; introducing molecular mixture to cell to enhance delivery of polynucleotide to cell
06/20/2000US6077833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
06/20/2000US6077832 Antiviral benzimidazole nucleoside analogues and a method for their preparation
06/20/2000US6077830 Bismuth salts of antibiotics of the moenomycin group, processes for their preparation, their use and pharmaceuticals comprising such salts
06/20/2000US6077828 Method for the prevention and treatment of cachexia and anorexia
06/20/2000US6077822 Drug salts
06/20/2000US6077714 Method for the preparation of free radical pharmaceuticals diagnostics and devices using selenium conjugates
06/20/2000US6077709 Nucleotide sequences that prevent the expression of a human polypeptide that prevent apoptosis in tumor cells; anticarcinogenic agents
06/20/2000US6077685 Tumor suppressor merlin and antibodies thereof
06/20/2000US6077683 Mixture of heparin partially desulfated at the 2-o position and a physiologically acceptable carrier; inhibits neutrophil enzymes without inducing anticoagulant activity; for respiratory system disorders, ischemia-reperfusion conditions
06/20/2000US6077675 Drug screening by contacting compound with recombinant cell which expresses a nucleic acid encoding the receptor and monitoring for binding or modulation of receptor; anticonvulsants; analgesics; cognition enhancers
06/20/2000US6077659 Treating erythrocyte/photosensitizer composition with vitamin e, alpha-tocopherol phosphate, alpha-tocopherol succinate, or 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
06/20/2000US6077545 Photosensitive composition, acid generator and organosilicon compound
06/20/2000US6077544 Protective coating to mask taste; tablet drug delivery; time-release agents
06/20/2000US6077543 Atomizing solutions to produce drops; lung drug delivery
06/20/2000US6077542 Heating valproic acid, dissolving sodium valproate therein, cooling below melting point
06/20/2000US6077541 Enteric coating; capsules
06/20/2000US6077539 Rapid bioavailability of metoclopramide; long acting non-steroidal antiinflammatory agent; free of ht3 receptor antagonists; side effect reduction
06/20/2000US6077538 Sodium carboxymethylcellulose, sodium bicarbonate, hydroxypropylmethyl cellulose, hydroxypropyl cellulose and magnesium stearate; analgesic and opiod drug delivery
06/20/2000US6077537 Non-sedating acrivastine product
06/20/2000US6077536 Pharmaceutical formulation
06/20/2000US6077531 Capsule with micronized progesterone suspension in oil and estradiol in microspheres; menopause
06/20/2000US6077530 Administering at different times to reduce side effects
06/20/2000US6077529 Applying lipid transfer protein in aqueous solution to surface of lung and oronasal passage
06/20/2000US6077528 Percutaneous preparation
06/20/2000US6077525 Use of conjugated linoleic acids
06/20/2000US6077520 Cosmetic composition
06/20/2000US6077512 Externally-applied medicine for curing black foot disease
06/20/2000US6077499 First conjugate of a tumor targeting moiety, a therapeutic agent, and first member of a binding pair; clearing agent; and second conjugate of the complementary binding member of the binding pair, and second therapeutic agent
06/20/2000US6077232 Anticoagulant composition
06/20/2000CA2215659C Morphinan hydroxamic acid compounds
06/20/2000CA2198536C Method of reducing tissue damage associated with ischemia
06/20/2000CA2198535C Method of increasing testosterone
06/20/2000CA2164619C Once-a-day metoprolol oral dosage form
06/20/2000CA2144845C Germicidal detergent-iodine compositions having reduced detergent content
06/20/2000CA2039212C Antineoplastic compounds and methods of using same
06/20/2000CA2013381C Selective adenosine receptor compounds
06/20/2000CA2011262C Use of mixed micelles
06/20/2000CA2001618C Gestodene-containing agent for transdermal administration
06/20/2000CA1341029C Peptidase inhibitors
06/17/2000CA2292246A1 New hydrazide derivatives, the procedure for preparing them and the pharmaceutical formulations that contain them
06/17/2000CA2290880A1 Cosmetic skin care compositions containing succinate compounds
06/15/2000WO2000034791A1 Assays for compounds which increase phospholipase a2 activity
06/15/2000WO2000034780A2 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
06/15/2000WO2000034778A1 Pgt and apoptosis
06/15/2000WO2000034481A2 DRUG TARGETS IN $i(CANDIDA ALBICANS)
06/15/2000WO2000034474A2 Growth factor homolog zvegf3
06/15/2000WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders
06/15/2000WO2000034467A1 Cancer cell vaccine
06/15/2000WO2000034447A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b
06/15/2000WO2000034338A2 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000WO2000034334A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
06/15/2000WO2000034308A2 Protein transduction system and methods of use thereof
06/15/2000WO2000034306A1 17β-ACYL-17α-PROPYNYL-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES
06/15/2000WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
06/15/2000WO2000034298A1 Glyceryl nucleotides, method for the production thereof and their use
06/15/2000WO2000034296A2 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
06/15/2000WO2000034295A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000WO2000034294A2 Tumor necrosis factor receptor homologue-1 ('trh1')
06/15/2000WO2000034285A2 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
06/15/2000WO2000034284A1 2,5-diazabicyclo[2.2.1]heptane derivatives, their preparation and therapeutic uses
06/15/2000WO2000034283A1 Novel triazolo(4,5-d)pyrimidine compounds
06/15/2000WO2000034281A1 Methotrexate derivatives
06/15/2000WO2000034279A1 1,4-diazabicyclo[3.2.2]nonane derivatives, their preparation and therapeutic application
06/15/2000WO2000034278A1 Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient
06/15/2000WO2000034276A1 Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
06/15/2000WO2000034268A1 Thiourea inhibitors of herpes viruses
06/15/2000WO2000034263A1 Benzofuran derivatives, their preparation and use
06/15/2000WO2000034261A2 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
06/15/2000WO2000034260A2 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
06/15/2000WO2000034258A2 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
06/15/2000WO2000034254A1 Novel compounds
06/15/2000WO2000034250A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
06/15/2000WO2000034248A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/15/2000WO2000034246A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative
06/15/2000WO2000034245A2 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
06/15/2000WO2000034244A1 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
06/15/2000WO2000034243A1 N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
06/15/2000WO2000034241A1 N-substituted 2-cyanopyrrolidines
06/15/2000WO2000034238A1 Thiourea inhibitors of herpes viruses
06/15/2000WO2000034237A2 Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
06/15/2000WO2000034236A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE
06/15/2000WO2000034230A1 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction
06/15/2000WO2000034228A1 Ion channel modulating agents
06/15/2000WO2000033979A1 Apparatus for separating particles of cohesive material according to size and process
06/15/2000WO2000033917A1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen
06/15/2000WO2000033888A2 Prodrug compounds and process for preparation thereof
06/15/2000WO2000033879A1 Method for the treatment of inflammation
06/15/2000WO2000033878A2 Stabilization of macrolides
06/15/2000WO2000033877A1 Anhydrous topical skin preparations
06/15/2000WO2000033876A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000WO2000033875A1 Chemotherapeutic composition and method
06/15/2000WO2000033874A2 Boron neutron capture therapy using pre-targeting methods
1 ... 6298 6299 6300 6301 6302 6303 6304 6305 6306 6307 6308 6309 6310 6311 6312 6313 6314 6315 6316 6317 6318 ... 7860